NCT05740345 is a clinical trial of Metformin in New Approaches in INOCA, sponsored by Pasquale Mone.

Who is sponsoring NCT05740345?

NCT05740345 is sponsored by Pasquale Mone.

What drugs are being tested in NCT05740345?

Interventions in NCT05740345: Metformin.

What condition does NCT05740345 study?

NCT05740345 studies New Approaches in INOCA.

Is NCT05740345 still recruiting?

NCT05740345 is currently completed. Last updated 23 February 2023.

Last reviewed 2023-02-23 · How we verify

NCT05740345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

New Approaches to INOCA

Completed Last updated 23 February 2023

What this trial tests

trial testing Metformin in New Approaches in INOCA in 3,000 participants. Completed in 15 January 2021.

Timeline

15 January 2016

Primary endpoint
15 January 2019

15 January 2021

Quick facts

Lead sponsor	Pasquale Mone
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	15 January 2016
Primary completion	15 January 2019
Estimated completion	15 January 2021

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

New Approaches in INOCA — all drugs for New Approaches in INOCA →

Sponsor

Pasquale Mone

Who can join

18 and older, any sex, with New Approaches in INOCA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ischemia with non-obstructive coronary arteries (INOCA) is common in patients with angina. INOCA has been associated with an increased risk of death, myocardial infarction, and stroke, particularly in symptomatic subjects. Previous investigations have evidenced the key role of poor glycemic control and diabetes in coronary microvascular dysfunction. Metformin is an old oral antidiabetic drug which is currently used to achieve glycemic control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Beneficial effects of metformin treatment in hyperglycaemic patients affected by ischaemia with no obstructive coronary artery.
Mone P, Varzideh F, Rainone A, Kansakar U, et al · · 2025 · cited 4× · PMID 39786492 · DOI 10.1093/cvr/cvae269

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05740345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pasquale Mone
Last refreshed: 23 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05740345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing